This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Annals

Advances Against Aspergillosis I

Edited by Edited by Karl V. Clemons (California Institute for Medical Research, San Jose, California), Malcolm Richardson (Wythenshawe Hospital, Manchester, UK), and David S. Perlin (New Jersey Medical School-UMDNJ, Newark, New Jersey)
Explore the Table of Contents
Advances Against Aspergillosis I

Published: December 2012

Volume 1272

Learn More

Aspergillosis, the leading fungal cause of mortality in immunocompromised patients, presents a serious worldwide challenge—particularly in the face of increasing antifungal resistance. Bringing together the world’s leaders in the Aspergillus and aspergillosis fields to promote cross-disciplinary collaboration among clinicians, industry, and scientific experts, the “Advances Against Aspergillosis” conference was held January 26–28, 2012 in Istanbul, Turkey. Among the topics included are the application of diagnostic markers to invasive aspergillosis in children, risk stratification for invasive aspergillosis in immunocompromised patients, use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis, immune regulation in idiopathic bronchiectasis, and management of chronic pulmonary aspergillosis.